Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.
Read More
The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.
Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.
Read More
Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.
Read More
Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.
Read More
When talking about healthcare, almost immediately the focus is on cost - not value. This is about to change as most western countries are not expected to be able to increase their healthcare expenditure any further, what with new treatments coming to the market that are ever more expensive and the rising burden of an aging population.
Read More
The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.
Read More
The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.
Read More
BaseLaunch helps build therapeutic ventures to the point where they can raise a Series-A financing round or similar.
Read More
The i4Challenge is an acceleration program for SME, startups and new projects focused on innovative solutions, new approaches and next-generation products or services for Industry 4.0.
Read More
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.
Read More
The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.
Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..
Read More
Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.
Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.
Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.
Read More
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.
Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.
Read More
In the fight against the coronavirus, Vas Narasimhan, CEO of Novartis, is above all pinning his hopes on a malaria drug. Narasimhan has claimed in an interview that this drug has proven in preclinical and initial clinical trials that it can destroy the virus. At the moment, patients are being enrolled for studies.
Read More
Basel/Liestal/Delémont – Because of the coronavirus crisis.the three sponsor cantons of BaselArea.swiss have adopted emergency aid measures in addition to those agreed by the Swiss government at national level. The cantons of Basel-Stadt, Basel-Landschaft and Jura will be supporting companies and other individuals affected to a substantial extent. The aim here is to mitigate the consequences of the coronavirus pandemic within the economic region of Basel Area.
Read More
The Basel-based pharmaceutical company Roivant Sciences wants to develop a special antibody for coronavirus patients. This is intended to help treat and prevent acute respiratory distress syndrome.
Read More
The US regulatory authority has authorized a test developed by the Basel-based pharmaceutical company Roche to detect the SARS-CoV 2 virus. Due to Roche’s work, numerous additional tests can be carried out in the USA, and for this reason Roche received the express thanks of President Trump.
Read More
The University of Basel is using computer-aided methods in its efforts to find an active substance to fight the coronavirus. A total of just under 700 million substances have been tested on a virtual basis. This has allowed interesting substances to be identified already.
Read More
Novartis and Roche feature among the hundred most innovative companies worldwide. This is from the Derwent Top 100 Global Innovators 2020 report. Roche is the only pharmaceutical company worldwide that has appeared in the list nine times.
Read More
Basel has long been one of the world’s most important locations within the pharmaceutical industry. But pharma firms are now starting to play an even bigger role in India as well. Both locations are influencing each other, as shown by the recently ended BioAsia event.
Read More
The pharmaceutical giant Roche has officially started building its new research center in Basel. Around 1,800 researchers should be able to work there by the end of 2023.
Read More
The FutureHealth Basel conference brought together experts, startups and those affected by digital healthcare. In addition to exploring the opportunities and challenges associated with digital healthcare, the conference also focused on strengthening the regional life sciences cluster.
Read More
Basel-based pharmaceutical Novartis is opening up its campus in Basel to external partners, including Switzerland Innovation Park Basel Area, which will establish an additional office there.
Read More
The Basel biotech company NBE-Therapeutics has successfully closed a series C financing round. The funds raised will help the company develop its leading product candidate to fight cancer.
Read More
The Czech biotech company Sotio has opened an office in the Technologiepark Basel. Sotio Biotech AG will be responsible for the company’s clinical development.
Read More
Coretag, a new dynamic biotech company, launches a radioligand platform technology for a range of therapeutic and diagnostic purposes. A radioligand is a radioactive biochemical that is used for diagnostic and therapeutic procedures or for studying the body’s receptor systems. Injected into the relevant tissue or administered into the bloodstream, the radioligand binds to its receptor on tumor cells surfaces. Coretag is determined to rapidly improve care with this platform technology.
Read More
The canton of Basel-Stadt offers one of the world’s most attractive tax burdens for companies, according to the latest BAK Taxation Index. With an effective tax burden of 11 per cent, it has ranked seventh in the world for the first time.
Read More
The Botnar Research Center for Child Health in Basel has started its research activities. The first four projects have now been selected. Together with the DayOne Accelerator from BaselArea.swiss, Basel is gradually evolving into a pediatrics hub.
Read More
Diabetes patients can use an app developed by Roche to determine their blood sugar levels on the basis of two photos taken on a cell phone camera. The Basel-based pharma group has now received the CE Mark for its app, paving the way for it to be marketed throughout Europe and in other countries around the world.
Read More
The pharmaceutical company BeiGene has won a Scrip Award that recognizes contributions across the pharma sector to improving healthcare. BeiGene’s European headquarters is located in Basel.
Read More
Substantial efforts are underway in Basel to develop new areas and create space for people and companies. The efforts were welcomed by investors at the 17th Basler Investorengespräch.
Read More
Corporate tax rates in the canton of Basel-Landschaft will be cut from a maximum of 20.7 percent today to 13.45 percent in 2025. This has been stipulated by the proposed Tax Regulation 17, which was approved on Sunday.
Read More
A new initiative has been launched to support innovative SMEs and startups in the canton of Basel-Landschaft in an effort to make the region even more attractive and strengthen its ability to innovate. The initiative will offer both financial assistance and advisory services.
Read More
BaselArea.swiss manages the DayOne initiative, which is now organizing the second round of the DayOne Accelerator. The participants are Digital Health startups promoting the health of children and young people.
Read More
BaselArea.swiss is working with selected organizations and Standortförderung Baselland to support the foundation of companies in the canton of Basel-Landschaft. At the root of the partnerships is the initiative startup baselland.
Read More
The Basel-based startup Artidis is developing a medical device based on nanotechnology to help with cancer diagnoses. The spin-off from the University of Basel has now been successfully integrated in the Texas Medical Center and will therefore have access to the US market.
Read More
The canton of Jura has more than 544 hectares of building land available, a study from the Federal Institute of Technology in Zurich (ETH) has found. Local authorities have now been presented with a detailed inventory.
Read More
Basel-based biotech company Vaximm has agreed a collaboration with IT company NEC. Vaximm wants to develop personalized cancer vaccines using NEC’s artificial intelligence (AI)-based prediction system.
Read More
The Basel startup Nutrix has won a competition at the Web Summit with its business concept. It has developed a nanosensor that measures glucose levels in users’ saliva to prevent diabetes. Nutrix is supported by the Venture Mentoring program of BaselArea.swiss and has been shortlisted for the DayOne Accelerator.
Read More
Researchers at the Allschwil pharmaceutical company Polyphor and the University of Zurich have discovered a novel antibiotics class. It has a unique mechanism of action that allows it to target multiple bacteria.
Read More
Switzerland Innovation Park Basel Area has opened its third location. The park is now represented in Jura alongside its locations in the Cantons of Basel-Landschaft and Basel-Stadt. This represents something of a milestone for the operators BaselArea.swiss.
Read More
Start-ups established in Basel raised more than 200 million euro in investments during the first half of 2019. Basel therefore leads the way in this regard within Switzerland, and stands in eighth place across Europe, as revealed by a new EY study.
Read More
Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform. Versameb was supported by the healthcare accelerator program BaseLaunch of BaselArea.swiss in 2017/18.
Read More
Basel-based start-up Tide Ocean turns ocean plastic waste into new products such as watches. It has now won a German design and technology award for its contribution to the circular economy.
Read More
© 2020 BaselArea | Terms & conditions | Privacy Policy
